First-MIND: Phase Ib study of R-CHOP + tafasitamab ± lenalidomide in newly diagnosed DLCBL

The use of tafasitamab and lenalidomide in R/R DLBCLПодробнее

frontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP in newly diagnosed high-risk DLBCLПодробнее

Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCLПодробнее

John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCLПодробнее

Dr. Burke on the Ongoing First-MIND Trial With Tafasitamab in DLBCLПодробнее

Tafasitamab-lenalidomide in R/R DLBCL: clinical trial results and real-world dataПодробнее

frontMIND: Tafasitamab + lenalidomide + R-CHOP vs R-CHOP in high-intermediate & high-risk DLBCLПодробнее

FrontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP for newly diagnosed high-risk DLBCLПодробнее

Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCLПодробнее

The use of tafasitamab in DLBCLПодробнее

Updates on tafasitamab for the treatment of DLBCLПодробнее

Smart Start for newly diagnosed DLBCL: rituximab/lenalidomide/ibrutinibПодробнее

The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trialsПодробнее

Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCLПодробнее

Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphomaПодробнее

Smart Stop: Moving away from R-CHOP in DLBCLПодробнее

RE-MIND2: observational study comparing tafasitamab+lenalidomide to available therapies in R/R DLBCLПодробнее

L-MIND Trial in Relapsed/Refractory DLBCLПодробнее

L-MIND Study: R/R DLBCLПодробнее